Observational studyMedicine2026
The impact of the COVID-19 pandemic in 2020 on the diagnosis, treatment, and cancer-specific survival of major urological cancers: An observational study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of the COVID-19 pandemic in 2020 on the diagnosis, treatment, and outcomes of major urological cancers remains poorly understood. Patients diagnosed with prostate cancer, bladder cancer, and kidney cancer were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Ordered logistic regression was used to evaluate the effect of the COVID-19 pandemic in 2020 on cancer stage at diagnosis. Logistic regression was employed to determine the impact of the pandemic on the diagnosis of different patient subgroups. Kaplan-Meier curves were used to evaluate cancer-specific survival (CSS). In the SEER-17 and SEER-22 datasets, the number of newly diagnosed cases of prostate cancer, bladder cancer, and kidney cancer decreased in 2020. Patients diagnosed with prostate cancer (OR = 1.04, 95% CI, 1.01-1.07, P = .016), bladder cancer (OR = 1.07, 95% CI, 1.01-1.14, P = .019), and kidney cancer (OR = 1.08, 95% CI, 1.02-1.14, P < .001) in 2020 were at a higher risk of advanced stages. Among the 3 cancers, patients with a median household income > 75,000 USD were more likely to be diagnosed in 2020, while urban and female patients (bladder and kidney cancers) tended to be diagnosed in 2018/2019. For prostate cancer (HR = 1.06, 95% CI, 0.97-1.15, P = .207), bladder cancer (HR = 1.04, 95% CI, 0.98-1.11, P = .188), and kidney cancer (HR = 1.03, 95% CI, 0.94-1.12, P = .496), no significant differences in CSS were observed between patients diagnosed in 2020 and those diagnosed in 2018/2019. The COVID-19 pandemic in 2020 led to a decrease in the number of diagnoses for prostate cancer, bladder cancer, and kidney cancer, with varying impacts on different patient subgroups. Patients diagnosed during this period were more likely to have later-stage disease. Additionally, no significant differences in CSS were observed between patients diagnosed during the COVID-19 pandemic in 2020 and those diagnosed in 2018/2019; however, this finding should be interpreted cautiously given the relatively short follow-up period and the potential influence of competing risks during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.